KLI

Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure

Metadata Downloads
Abstract
Immune checkpoint inhibitors (ICIs) have become a standard treatment for metastatic urothelial carcinoma (mUC) after platinum-based chemotherapy. However, the prognostic factors for patients with mUC receiving ICIs are not well established. We retrospectively collected clinical and laboratory data and reviewed the survival outcomes of patients with mUC who were treated with ICIs after platinum-based chemotherapy. We used univariate and multivariable Cox proportional hazard models to identify independent prognostic factors, and the concordance index (C-index) to evaluate the performance of the new prognostic model. In addition, bootstrap analysis was employed for internal validation of the prognostic model. A total of 224 patients were included in the study. With a median follow-up of 10.5 months (interquartile range, 5.1-17.4 months), median overall survival (OS) was 13.6 months (95% confidence interval [CI], 9.7-17.3 months). In multivariable analysis, independent prognostic factors predicting adverse OS were the presence of liver metastasis (LM), hypoalbuminemia, and neutrophil-lymphocyte ratio (NLR) >5. When patients were categorized into 3 risk groups, median OS was not reached (NR) (95% CI, 17.3-NR), 9.5 months (6.8-NR), and 2.9 months (2.3-4.4) for patients with a score of 0, 1, and 2+, respectively. The C-index for the new model was 0.763 (95% CI, 0.739-0.787). A novel prognostic model, including LM, hypoalbuminemia, and NLR, was developed and validated to estimate OS in patients with platinum-refractory disease on second- or subsequent-line ICI therapy. Further investigations, including prospective validation, are needed.
Author(s)
Joo-Hwan ParkInkeun ParkIn-Ho KimJoon Young HurInhwan HwangChan KimHyo-Jeong KimChi Hoon MaengKwonoh ParkMin-Young LeeHyo Jin LeeJoo Young JungBhumsuk KeamSe Hoon ParkJae Lyun Lee
Issued Date
2022
Type
Article
Keyword
Immune checkpoint InhibitorOverall survivalPlatinum chemotherapyPrognostic modelUrothelial carcinoma
DOI
10.1016/j.currproblcancer.2022.100848
URI
https://oak.ulsan.ac.kr/handle/2021.oak/13769
Publisher
CURRENT PROBLEMS IN CANCER
Language
영어
ISSN
0147-0272
Citation Volume
46
Citation Number
3
Citation Start Page
100848
Appears in Collections:
Medicine > Nursing
공개 및 라이선스
  • 공개 구분공개
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.